GlassScriptPhysician profile
Amanda Sher Fallos
NPI 1225364748
$11,607.92
in general payments reported to CMS, 2019-2025
58 companies · $2,130 in 2025
The $2,130 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,680 · 2022: $2,167 · 2023: $2,495 · 2024: $2,136 · 2025: $2,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,760.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,025.73 | 2021-2025 | |
| Novo Nordisk INC | $1,678.16 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $786.09 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $770.95 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $756.52 | 2021-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $623.56 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $501.99 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $286.44 | 2021-2023 | Spravato |
| Exact Sciences Corporation | $275.41 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $275.10 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.12 | 2021-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $217.61 | 2025 | Korlym |
| Lilly USA, LLC | $206.78 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $204.28 | 2021-2023 | Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.50 | 2021-2025 | Jardiance, Tradjenta, Ofev |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Fallos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.